Dr Rafael Fonesca reviews data from the TriMM-2 study presented at ASCO 2023 investigating combination talquetamab plus daratumumab for patients with relapsed/refractory multiple myeloma, highlighting a 78% response rate to talquetamab, but noting side effects like CRS and infections.
Assessing The Rationale Behind Triplet Regimens in RRMM
June 14th 2024During a Case-Based Roundtable® event, Ariel Grajales-Cruz, MD, discussed the long-term results of the phase 3 IKEMA study that build the rationale for use of the triplet therapy isatuximab, carfilzomib, and dexamethasone, in patients with relapsed/refractory multiple myeloma in the second article of a 2-part series.
Read More
Grajales-Cruz Interprets Data for Earlier- Line CAR T-Cell Therapy in R/R MM
June 8th 2024During a Case-Based Roundtable® event, Ariel F. Grajales-Cruz, MD, discussed data from the KarMMa-3 trial of idecabtagene vicleucel and real-world data on the CAR T-cell therapy in patients with relapsed/refractory multiple myeloma.
Read More
Khouri Analyzes How Daratumumab-Based Quadruplet Therapy Achieves MRD States in Multiple Myeloma
June 7th 2024During a Case-Based Roundtable® event, Jack Khouri, MD, discussed data from the GRIFFIN, PERSEUS, and MASTER trials that investigated quadruplet therapy in patients with newly diagnosed multiple myeloma.
Read More